Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*

Fiorino, Gionata; Peyrin–Biroulet, Laurent; Naccarato, Patrizia; Szabó, Hajnalka; Sociale, Orsola; Vetrano, Stefania; Fries, Walter; Montanelli, Alessandro; Repici, Alessandro; Malesci, Alberto; Danese, Silvio

doi:10.1002/ibd.21800

Cited by 164 publications

(122 citation statements)

References 23 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Assessing the amount of anti-pneumococcal antibodies, the infliximab group showed a 2.69-fold increase in antibody titer, compared with a 5.71-fold increase in the control group. 64 These results were reaffirmed in a recent prospective study of Korean CD patients, which found that the female sex and anti-TNF therapy were significant nonresponse predictors to pneumococcal polysaccharide vaccination (P = 0.015, P = 0.048, respectively). 65 PCV-13 vaccine, in which polysaccharides are conjugated to an immunogenic carrier protein, is expected to be more immunogenic than PPV23.…”

Section: Biologics Therapy In East Asiamentioning

confidence: 60%

Understanding the complications of anti‐tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease

Cheon

2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

Remarkable advances have been made in the treatment of inflammatory bowel disease since the introduction of anti‐tumor necrosis factor‐α agents, especially for patients who are refractory to or cannot tolerate conventional therapies. Currently, infliximab, adalimumab, and golimumab are available in the East Asian medical market, and these agents have been shown to be effective for inducing and maintaining long‐term remission of inflammatory bowel disease. Despite their clinical benefits, anti‐tumor necrosis factor therapy can also lead to increased vulnerability to infections, development of autoimmune diseases and malignancy, and decreased immunogenicity of vaccinations. Because infectious diseases, such as tuberculosis, hepatitis, and influenza, remain major health problems in East Asia, more cautious use of biologics is needed. To further improve treatment efficacy and safety, close monitoring of inflammation, regular surveillance for malignancy, and regularly scheduled vaccinations are needed. Treatment strategies for biologics should be customized to meet the needs of different patients.

show abstract

Section: Biologics Therapy In East Asiamentioning

confidence: 60%

Understanding the complications of anti‐tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease

Cheon

2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Die Pneumokokkenimpfung zeigt bei nicht immunsupprimierten IBD-Patienten ein normales Ansprechen, bei immunsupprimierten Patienten, insbesondere jenen unter TNFα-Blockern ist das Ansprechen jedoch signifikant geringer [125]. Deshalb sollten diese Patienten möglichst vor Beginn der ISP gegen Pneumokokken geimpft werden [114].…”

Section: Gastroenterologie/entzündliche Darmerkrankungenunclassified

Impfungen bei Immundefekten/Immunsuppression – Expertenstatement und Empfehlungen

Wiedermann

Sitte

Burgmann

et al. 2016

Wien Klin Wochenschr

View full text Add to dashboard Cite

“…While data concerning the need for revaccination with conjugated vaccine are scant, PPSV23 revaccination after 5 years is recommended for immunocompromised patients [34] . However, the response to Streptococcus pneumoniae vaccinations may be impaired in IBD patients treated with immunomodulators, particularly when they are used in combination [35,36] . For this reason, it would be advisable to perform vaccinations for pneumococcal infections before starting immunosuppressive drugs.…”

Section: Streptococcus Pneumoniaementioning

confidence: 99%

What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Andrisani

Armuzzi

Marzo

et al. 2016

WJGPT

View full text Add to dashboard Cite

increased risk of opportunistic infections, in particular of viral or bacterial etiology. Despite the existence of international guidelines, many gastroenterologists have not adopted routine screening and vaccination in those patients with IBD, which are candidate for biologic therapy. Available strategies to screen, diagnose and prevent bacterial and viral infections in patients with IBD prior to start biological therapy are discussed in this review. Core tip: The increasing use of biologics as a mainstay of therapy in inflammatory bowel disease (IBD) is associated with an increased risk for a variety of infections, many of which are preventable by prior screening and vaccination. While immunocompetent IBD patients can be vaccinated using standard vaccination schedule, special guidelines need to be followed for IBD patients getting immunosuppressive therapy (IST). This article provides a review of the issues surrounding immunizations in the IBD patient and a practical guide for clinicians regarding the appropriate screening for infections and vaccinations to administer both before and during IST. AbstractThe use of biological agents and immunomodulators for inflammatory bowel disease (IBD) is associated with an REVIEWSubmit a

show abstract

Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: A prospective study*

Abstract: Anti-TNF therapy alone or in combination with azathioprine impairs the response to pneumococcal vaccination in patients with IBD. All patients with IBD should therefore be vaccinated before starting anti-TNF therapy.

Cited by 164 publications

References 23 publications

Understanding the complications of anti‐tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease

Understanding the complications of anti‐tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease

Impfungen bei Immundefekten/Immunsuppression – Expertenstatement und Empfehlungen

What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients?

Contact Info

Product

Resources

About